Quantcast

Latest Peyronie's disease Stories

2014-10-21 08:33:47

- Label expansion to broaden patient base who may benefit from nonsurgical collagenase therapy LYNBROOK, N.Y., Oct. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics...

2014-10-20 20:26:38

Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., Oct. 20, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX(® )(collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same...

2014-10-08 16:26:59

LYNBROOK, N.Y., Oct. 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), today announced with great sadness that Max Link, Ph.D., a member of its Board of Directors, passed away unexpectedly on October 5, 2014. He was 74 years old. Dr. Link served as the Chair of the Compensation Committee, as the Audit Committee Financial Expert and as a member of the Board's Audit, Compensation and Nominating and Corporate Governance Committees. "We are very saddened by the...

2014-09-29 08:29:25

Erectile Dysfunction in Younger and Older Men Has Many Overlooked Causes. NEW YORK, Sept. 29, 2014 /PRNewswire-USNewswire/ -- Specialists in treatment of erectile dysfunction recognize that ED is more prevalent than previously recognized. http://photos.prnewswire.com/prnvar/20140408/NY00250LOGO Symptoms of erectile dysfunction can affect younger men as well as older men. Men often experience difficulty obtaining an erection hard enough for penetration or difficulty maintaining...

2014-09-19 08:26:01

LYNBROOK, N.Y., Sept. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the 21(st) Annual BioCentury NewsMakers in the Biotech Industry Conference. The presentation will take place on Friday, September 26, 2014 at 3:00 p.m....

2014-09-18 16:28:15

- Data suggest support for potential label expansion of XIAFLEX for Dupuytren's contracture to include treatment of two affected joints concurrently; PDUFA date is October 20, 2014 - LYNBROOK, N.Y., Sept. 18, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced that positive...

2014-09-18 08:28:56

Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution of...

2014-08-28 08:27:24

Study Results of Concurrent CCH Injections to Treat Two Dupuytren's Contracture Cords with Delayed Finger Extension Selected for Best Paper Session; Data Support Safe and Effective Use of CCH for Treatment of Two Affected Joints Concurrently CHESTERBROOK, Pa., Aug. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data from trials evaluating the use of collagenase clostridium histolyticum (CCH) for treating two...

2014-08-27 08:27:00

CHESTERBROOK, Pa., Aug. 27, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Morgan Stanley Healthcare Conference to be held September 8-10, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 10:55 a.m. ET on Wednesday,...

2014-08-21 20:22:34

LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced positive, statistically significant results from a randomized, double-blind Phase 2a study of CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The results...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related